Head & Neck Cancers | Specialty

Investigational PI3K-γ Inhibitor Eganelisib Plus Nivolumab Elicits Early Efficacy in Head and Neck Cancer, Melanoma

November 13th 2020

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

CD47 Blocker ALX148 Safe to Combine With Antibody Regimens, Chemotherapy in Gastric/GEJ and HNSCC

November 13th 2020

November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.

Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer

November 12th 2020

In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.

Dr. Saba Discusses Ongoing Trials in Head and Neck Cancer

November 12th 2020

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

Ho Highlights the Latest Breakthroughs in Head, Neck, and Thyroid Cancers

November 11th 2020

Alan L. Ho, MD, PhD, highlights the great strides that have been made with head and neck cancer, including those with rarer diseases like thyroid cancer and salivary gland cancers, due to a greater understanding of disease biology and genomics.

AL101 Shows Promising Activity in Recurrent/Metastatic Adenoid Cystic Carcinoma With NOTCH Activating Mutations

November 4th 2020

The investigational small molecule, γ-secretase inhibitor AL101 monotherapy was found to elicit deep responses with a significant disease control rate in patients with recurrent or metastatic adenoid cystic carcinoma harboring NOTCH activating mutations.

Tipifarnib Shows Potential in HRAS-Mutant Head and Neck Cancers

November 4th 2020

Investigators are testing tipifarnib, a novel drug that inhibits a critical enzyme needed for HRAS activation, in patients with head and neck squamous cell carcinoma whose tumors harbor the mutation.

Axitinib Demonstrates Survival Benefit in Heavily Pretreated Unresectable Recurrent, or Metastatic Head and Neck Cancer

November 1st 2020

Heavily pretreated patients with unresectable recurrent or metastatic head and neck squamous cancer experienced an improvement in survival following treatment with axitinib.

Dr. Cohen on the Design on the SPEARHEAD-2 Trial in Head and Neck Cancer

October 29th 2020

Ezra Cohen, MD, FRCPSC, FASCO, discusses the design of the phase 2 SPEARHEAD-2 trial with ADP-A2M4 plus pembrolizumab in patients with recurrent or metastatic head and neck cancer.

Dana-Farber Announces Center for Salivary and Rare Head and Neck Cancers

October 6th 2020

Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive cancers arising from the head and neck.